Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R03) | Apply Online

Opportunity Summary:

The grant opportunity titled "Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R03)" (Funding Opportunity Number RFA-DA-09-019) is a National Institutes of Health request for applications led jointly by the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS). It is designed to support small, focused research projects that help clarify how chronic pain reshapes the central nervous system (CNS), and how those pain-related brain and spinal cord changes overlap with, differ from, or potentially contribute to the kinds of CNS alterations seen in drug addiction. The underlying idea is that chronic pain and substance use disorders can both involve long-lasting neurobiological adaptations, and the FOA is aiming to push research that directly compares these processes rather than studying them in isolation.

Scientifically, the announcement is centered on three closely related questions. First, it seeks studies that characterize the CNS changes that occur during chronic pain states, including how those changes develop and persist over time. Second, it encourages research on how analgesics from different drug classes influence pain-induced CNS changes, meaning investigators can look at whether effective pain relief reverses, masks, accelerates, or otherwise modifies the neural adaptations associated with chronic pain. Third, it highlights the importance of studying what happens when analgesics are taken in the absence of pain, especially for drugs with abuse potential, because these exposures may produce CNS changes that resemble or prime the brain for addiction-like adaptations. Across all three areas, the temporal course is explicitly called out as a priority, signaling interest in when particular neural changes emerge, how long they last, and whether there are critical windows where interventions might shift the trajectory.

A major theme of the FOA is comparative work that identifies both shared and unique mechanisms across pain, analgesia, and drug abuse. In practice, this could include studies that map overlapping circuits, cellular changes, or molecular pathways involved in reward, motivation, stress responsivity, learning and memory, affective processing, and sensory modulation, while also teasing apart what is specific to persistent pain versus what is specific to drug exposure or misuse. The FOA also emphasizes influences that shape these CNS outcomes, including environmental factors and genetic factors, reflecting an interest in vulnerability and resilience: why some individuals develop problematic patterns (chronic pain persistence, maladaptive analgesic responses, or addiction) while others do not under similar exposures.

In terms of funding mechanism, this opportunity uses the NIH R03 small grant mechanism, which is typically used for short, well-defined projects such as pilot studies, feasibility work, secondary analyses, or targeted hypothesis tests that can generate preliminary data for larger grants. This FOA is described as running in parallel with companion announcements of the same scientific scope using other NIH mechanisms: an R01 version (RFA-DA-09-017) for larger, full-scale projects and an R21 version (RFA-DA-09-018) for exploratory/developmental studies. The presence of all three mechanisms signals that NIH wanted to support the same overall research direction at multiple project sizes, from small proof-of-concept studies through more comprehensive research programs.

The agencies set aside an estimated total of $2,375,000 across NIDA and NINDS for this FOA and its companion announcements. Specifically, NIDA set aside $2,000,000 and anticipated supporting roughly 6 to 10 grant applications, while NINDS set aside $375,000 and anticipated supporting about two grants across this FOA and the companion R01 and R21. In other words, most of the available support was expected to come through NIDA, with additional contributions from NINDS to ensure neuroscience and neurological disorder perspectives were represented alongside addiction science.

Eligibility is broad and includes many common NIH applicant types: public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits), for-profit organizations (including small businesses and other for-profits), and a variety of government entities (state, county, city/township, special districts, and certain public housing authorities). The FOA also lists a wide range of additional eligible applicants such as federally recognized and other tribal governments and organizations, tribally controlled colleges and universities, historically Black colleges and universities, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, faith-based and community-based organizations, U.S. territories and possessions, and even non-U.S. entities (foreign organizations) and regional organizations. There is no cost sharing or matching requirement, which is typical for NIH research grants.

Administratively, the opportunity was posted on December 8, 2008, with an original and current closing date of January 28, 2009, and it was archived on February 28, 2009. The CFDA numbers associated with the program are 93.279 (Drug Abuse and Addiction Research Programs) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders), reflecting the joint addiction and neuroscience focus. The full announcement was hosted through the NIH grants guide, and the NIH Office of Extramural Research provided webmaster contacts for access or linking issues.

Overall, this R03 FOA is best understood as a targeted NIH effort to bring pain biology and addiction biology into the same experimental frame, with a particular emphasis on how chronic pain and analgesic exposure reshape CNS function over time, how those neuroadaptations may overlap with addiction-related changes, and which biological and contextual factors determine the direction and severity of those changes.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R01)

Previous opportunity: Human, Social, Cultural and Behavioral Sciences basic research, applied research and advanced

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA DA 09 019

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA DA 09 019) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 09 019", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.